Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medroxyprogesterone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medroxyprogesterone Acetate SCHEMBL13941346 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL14148331 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL14262777 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4217893 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4276 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6835475 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL10080145 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6563018 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL22761990 | 1.00 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4277 | 0.98 | NR3C1 (0.96) | NR3C1LMNACYP3A4PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277285-B1 | ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY | UNIV CALIFORNIA (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3200802-B1 | COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION | UNIV CALIFORNIA (US) | 2023-07-12 | — | — | EP | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | claimed |
| CN-209900844-U | System for 6-methine-17 alpha-hydroxyprogesterone acetate mother liquor purification | 湖北丹澳药业有限公司 | 2020-01-07 | — | — | CN | claimed |
| US-10406169-B2 | Methods of monitoring estriol therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-10 | — | — | US | claimed |
| US-9962395-B2 | Compositions and methods for maintaining cognitive function | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-08 | — | — | US | claimed |
| US-20180085379-A1 | METHODS OF MONITORING ESTRIOL THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | claimed |
| US-20170290845-A1 | ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-12 | — | — | US | claimed |
| US-20170232003-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-17 | — | — | US | claimed |
| EP-3188735-A1 | ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY | The Regents of the University of California (US) | 2017-07-12 | — | — | EP | claimed |
| US-6828120-B2 | Preparation of 11 beta ,17 alpha ,21- trihydroxy-6 alpha -methylpregna-1,4-diene-3,20-dione 21-acetate; obtain chemical intermediates, incubate reaction mix and enzymes, recover product | PHARMACIA AND UPJOHN COMPANY | 2004-12-07 | — | — | US | claimed |
| EP-1399463-A1 | PROCESS TO PREPARE 11$g(b),17$g(a),21-TRIHYDROXY-6$g(a)-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-24 | — | — | EP | claimed |
| US-20030044885-A1 | Process to prepare 11beta, 17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | CRIA, INC. | 2003-03-06 | — | — | US | claimed |
| WO-2002102826-A1 | PROCESS TO PREPARE 11β,17α,21-TRIHYDROXY-6α-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-27 | — | — | WO | claimed |
| EP-0477195-A1 | SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1992-04-01 | — | — | EP | claimed |
| WO-1990015816-A1 | SURAMIN TYPE COMPOUNDS AND ANGIOSTATIC STEROIDS TO INHIBIT ANGIOGENESIS | THE UPJOHN COMPANY (US) | 1990-12-27 | — | — | WO | claimed |
| US-4154748-A | Phosphate catalyzed acylation of steroidal tertiary alcohols | THE UPJOHN COMPANY (US) | 1979-05-15 | — | — | US | claimed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | claimed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | NRP1, PGR, TNFRSF1A | PGR 2/4885NR3C1 36/4885LMNA 3580/4885 |
| US-20030044885-A1 | Process to prepare 11beta, 17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | CYP17A1, CYP51A1, HSD17B11 | PGR 339/4885NR3C1 103/4885LMNA 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.